Cholesteryl Ester Storage Disease (CESD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Cholesteryl ester storage disease (CESD) is a chronic liver disease that results from an autosomal recessive condition due to a deficiency of lysosomal acid lipase (LAL). The LAL gene is situated on chromosome 10q23.2-q23.3, and this enzyme plays a crucial role in breaking down triglycerides and cholesteryl esters within lysosomes. Elevated cholesterol levels, high triglycerides, a deficiency of HDL, and the abnormal accumulation of lipids in various organs characterize CESD. This leads to hepatomegaly in the liver due to hepatic steatosis and fibrosis, potentially resulting in micronodular cirrhosis. Onset typically occurs during childhood or adolescence, and males and females are equally affected. Sadly, patients rarely reach the age of 30. Biochemically, this disorder is characterized by a significant reduction in lysosomal acid lipase activity.
Thelansis’s
“Cholesteryl Ester Storage Disease (CESD) Market Outlook, Epidemiology,
Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers
disease overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Cholesteryl
Ester Storage Disease (CESD) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Cholesteryl Ester
Storage Disease (CESD) across 8 MM market from the centre of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Cholesteryl
Ester Storage Disease (CESD) Market Forecast Patient Based Forecast Model (MS.
Excel Based Automated Dashboard), which Data Inputs with sourcing, Market
Event, and Product Event, Country specific Forecast Model, Market uptake and
patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and
pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Tags: Cholesteryl
Ester Storage Disease (CESD), Cholesteryl Ester Storage Disease (CESD) market outlook, Cholesteryl Ester Storage Disease
(CESD) competitive landscape, Cholesteryl
Ester Storage Disease (CESD) market forecast,
Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)

Comments
Post a Comment